Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India

Clinical Infectious Diseases

Volumn 44, Issue 9, 2007, Pages 1235-1244

  Shah, Bijal ^a   Walshe, Louise ^b   Saple, Dattary G ^d   Mehta, Shruti H ^c   Ramnani, Jeetender P ^c   Kharkar, R D ^d   Bollinger, Robert C ^b,c   Gupta, Amita ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Human Healthcare and Research Foundation   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOATING; CLINICAL TRIAL; COLIC; COMORBIDITY; CORRELATION ANALYSIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG COST; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH SURVEY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; INTERVIEW; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRIVATE HOSPITAL; RASH; RNA ANALYSIS; SELF REPORT; SIDE EFFECT; SKIN COLOR; SKIN TINGLING; STOMACH PAIN; VIRUS DETECTION; VIRUS INHIBITION; VOMITING; CROSS-SECTIONAL STUDY; HEALTH CARE FACILITY; MIDDLE AGED; OUTPATIENT DEPARTMENT; URBAN POPULATION; VIROLOGY; VIRUS LOAD;

ADULT; AMBULATORY CARE FACILITIES; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH FACILITIES, PROPRIETARY; HIV INFECTIONS; HUMANS; INDIA; MALE; MIDDLE AGED; PATIENT COMPLIANCE; URBAN POPULATION; VIRAL LOAD;

EID: 34247249920     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513429     Document Type: Article

References (42)

1. Laurent C, Kouanfack C, Koulla-Shiro S, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 2004; 364:29-34.
2. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95.
3. Palella FJ Ir, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
4. Wood E, Hogg RS, Yip B, et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis 2003; 188:1421-5.
5. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: overview of published literature. J Acquir Immune Defic Syndr 2002; 31(Suppl 3): S123-7.
6. Press N, Tyndall MW, Wood E, Hogg RS, Montaner IS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S112-7.
7. Kuritzkes DR. Preventing and managing antiretroviral drug resistance. AIDS Patient Care STDS 2004; 18:259-73.
8. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-66.
9. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347: 385-94.
10. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
11. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis 2003; 37: 1112-8.
12. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 Report on the global AIDS epidemic. Available at: http://www.unaids.org/en/HIV_data/ 2006GlobalReport/default.asp. Accessed 5 January 2007.
13. National Commission of Macroeconomics and Health Ministry of Health and Family Welfare and Government of India. Financing and delivery of health care services in India. Available at: https://www.who.int/macrohealth/action/ Background%20Papers%20report.pdf. Accessed 2 October 2006.
14. Chesney MA, Ickovics IR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-66.
15. Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S103-6.
16. Kemerer V. Tool kit to evaluate health-related quality of life among persons receiving care for and living with HIV/AIDS in resource-constrained settings. 2003. Available at: http://www.jhsph.edu/MOS-HIV/images/ Tool%20kit%20to%20evaluate%20health.pdf. Accessed 6 October 2006.
17. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-33.
18. World Health Organization (WHO). HIV/TB clinical manual. 2nd ed. WHO/HTM/TB 2004.329. Geneva: WHO, 2004. Available at: http://www.who.int/tb/publications/who_htm_tb_2004_329/en/index.html. Accessed 9 May 2006.
19. Ramchandani SR, Mehta SH, Saple DG, et al. Knowledge, attitudes, and practices of antiretroviral therapy among HIV-infected adults attending public and private clinics in India. AIDS Patient Care STDS 2007; 21:129-42.
20. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679-90.
21. Murphy DA, Marelich WD, Hoffman D, Steers WN. Predictors of antiretroviral adherence. AIDS Care 2004; 16:471-84.
22. Singh N, Berman SM, Swindells S, et al. Adherence of human immunodeficiency virus-infected patients to antiretroviral therapy. Clin Infect Dis 1999; 29:824-30.
23. Kumarasamy N, Safren SA, Raminani SR, et al. Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: a qualitative study. AIDS Patient Care STDS 2005; 19:526-37.
24. Safren SA, Kumarasamy N, James R, Raminani S, Solomon S, Mayer KH. ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care 2005; 17:853-62.
25. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-9.
26. Gifford AL, Bormann JE, Shively MI, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr 2000; 23:386-95.
27. Pinheiro CA, de-Carvalho-Leite JC, Drachler ML, Silveira VL. Factors associated with adherence to antiretroviral therapy in HIV/AIDS patients: a cross-sectional study in Southern Brazil. Braz J Med Biol Res 2002; 35:1173-81.
28. Weidle PJ, Ganera CE, Irwin KL, et al. Adherence to antiretroviral medications in an inner-city population. J Acquir Immune Defic Syndr 1999; 22:498-502.
29. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
30. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997; 337:725-33.
31. Kirk O, Pedersen C, Law M, et al. Analysis of virological efficacy in trials of antiretroviral regimens: drawbacks of not including viral load measurements after premature discontinuation of therapy. Antivir Ther 2002; 7:271-81.
32. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363:1253-63.
33. Amoroso A, Spencer DE, Redfield RR. Improving on success: what treating the urban poor in America can teach us about improving antiretroviral programmes in Africa. AIDS 2004; 18(Suppl 3):S39-43.
34. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131:81-7.
35. Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d'Ivoire. AIDS 2003; 17(Suppl 3):S5-15.
36. Weidle PJ, Malamba S, Mwebaze R, et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 2002; 360:34-40.
37. Kamat VR. Private practitioners and their role in the resurgence of malaria in Mumbai (Bombay) and Navi Mumbai (New Bombay), India: serving the affected or aiding an epidemic? Soc Sci Med 2001; 52:885-909.
38. Brosgart CL, Mitchell TF, Coleman RL, Dyner T, Stephenson KE, Abrams DI. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis 1999; 28:14-22.
39. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334: 701-6.
40. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugyenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. Int J STD AIDS 2005; 16:38-41.
41. Carballo E, Cadarso-Suarez C, Carrera I, et al. Assessing relationships between health-related quality of life and adherence to antiretroviral therapy. Qual Life Res 2004; 13:587-99.
42. Mahal A, Rao B. HIV/AIDS epidemic in India: an economic perspective. Indian J Med Res 2005; 121:582-600.